Abstract Recently it was reported that microRNA from the miR-17 ~ 92 family may have a key role in chronic lymphocytic leukemia (CLL). Here, we designed specific oligonucleotides to target endogenous miR-17 (antagomiR17). In-vitro administration of antagomiR17 effectively reduced miR-17 expression and the proliferation of CLL-like MEC-1 cells. When injected in-vivo in tumor generated by the MEC-1 cells in SCID mice, antagomiR17 dramatically reduced tumor growth and significantly increase survival. Altogether, our results provide the rationale for the use of antagomiR17 as a novel potential therapeutic tool in CLL and in other lymphoproliferative disorders where miR-17 has a driver role in tumor progression.

Dereani, S., Macor, P., D'Agaro, T., Mezzaroba, N., Dal Bo, M., Capolla, S., et al. (2014). Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia. JOURNAL OF HEMATOLOGY & ONCOLOGY [10.1186/s13045-014-0079-z].

Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia.

DEL POETA, GIOVANNI;
2014-10-23

Abstract

Abstract Recently it was reported that microRNA from the miR-17 ~ 92 family may have a key role in chronic lymphocytic leukemia (CLL). Here, we designed specific oligonucleotides to target endogenous miR-17 (antagomiR17). In-vitro administration of antagomiR17 effectively reduced miR-17 expression and the proliferation of CLL-like MEC-1 cells. When injected in-vivo in tumor generated by the MEC-1 cells in SCID mice, antagomiR17 dramatically reduced tumor growth and significantly increase survival. Altogether, our results provide the rationale for the use of antagomiR17 as a novel potential therapeutic tool in CLL and in other lymphoproliferative disorders where miR-17 has a driver role in tumor progression.
23-ott-2014
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15 - MALATTIE DEL SANGUE
English
Con Impact Factor ISI
Dereani, S., Macor, P., D'Agaro, T., Mezzaroba, N., Dal Bo, M., Capolla, S., et al. (2014). Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia. JOURNAL OF HEMATOLOGY & ONCOLOGY [10.1186/s13045-014-0079-z].
Dereani, S; Macor, P; D'Agaro, T; Mezzaroba, N; Dal Bo, M; Capolla, S; Zucchetto, A; Tissino, E; DEL POETA, G; Zorzet, S; Gattei, V; Bomben, R
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/99607
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 18
social impact